Joanna Wolak, Endlyz Therapeutics CEO
March 31, 2025 12:01 AM EDT
Financing
Startups

Ex­clu­sive: SV Health de­buts Parkin­son's biotech with back­ing from Ab­b­Vie and oth­ers

Kyle LaHucik

Senior Reporter

SV Health In­vestors, fresh off a $250 mil­lion fund for de­men­tia-fo­cused biotechs, has un­veiled its lat­est ef­fort, this time to ad­vance new …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

TRENDING NOW

Bris­tol My­ers CEO sig­nals deal­mak­ing will be a top pri­or­i­ty in 2025

Drug­mak­ers see a sub­stan­tial, but man­age­able, hit to busi­ness from tar­iffs. But the worst may lie ahead

Roche CEO warns that tar­iffs could im­pact deal­mak­ing

Ver­san­t's lat­est biotech fo­cus­es on in­flam­ma­to­ry dis­eases

Cari­bou lays off 32% of staff, cuts lu­pus cell ther­a­py pro­gram be­fore first pa­tient

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times